Dirk Kersten Sells Shares of Dyne Therapeutics
Insider Dirk Kersten sold shares in a planned transaction, totaling over $3.9 million.
Key Points
- Dirk Kersten sold 190,676 shares of Dyne Therapeutics, Inc., valued at $3.92 million, in a planned transaction on June 22, 2026.
- Dyne Therapeutics, Inc. has a market cap of approximately $3.45 billion and a 52-week range between $8.06 and $25.00.
- Analysts maintain a strong buy consensus with a mean target price of $38.25, reflecting optimism about Dyne's future.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Dirk Kersten sold 190,676 shares of Dyne Therapeutics, Inc. (NasdaqGS: DYN) in a planned transaction. This sale was valued at approximately $3.92 million, with shares sold at an average price of $20.57 each.
Insider Buying and Selling at Dyne Therapeutics, Inc.
Dirk Kersten has been active in trading Dyne Therapeutics shares recently. On June 23, he sold another 73,286 shares at an average price of $21.05, and earlier in the month, he sold 46,901 shares on June 18 and 37,454 shares on June 17. Each of these transactions was part of a planned series of sales. Meanwhile, Barry Greene purchased 57,463 shares on June 22.
Other Institutional Activity in Dyne Therapeutics
T. Rowe Price Investment Management, Inc. grew its holdings by 13,245,712 shares, ending with 30,785,801 shares worth about $558.15 million. Janus Henderson Group PLC trimmed its position by 240,346 shares, resulting in 13,647,376 shares valued at $247.43 million. BlackRock, Inc. added 509,032 shares, bringing its total to 11,699,870 shares worth approximately $212.12 million. Atlas Venture Life Science Advisors, LLC maintained its position with 9,130,465 shares valued at $165.54 million. FMR LLC increased its stake by 2,339,059 shares, totaling 8,908,980 shares worth about $161.52 million.
Dyne Therapeutics, Inc. Stock Down 19.2%
Shares of Dyne Therapeutics traded near $20.26 on Thursday. The company has a market cap of around $3.45 billion and a forward P/E ratio that isn't meaningful due to its current lack of profitability. With a beta of 1.083, the stock has experienced a 52-week low of $8.06 and a high of $25.00. Its 50-day moving average is $18.29, while the 200-day moving average stands at $17.67. Dyne maintains a strong balance sheet with a current ratio of 19.92 and a quick ratio of 18.97.
$DYN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 15, 2026, Evercore ISI Group maintained a buy rating with a $33.00 price target. Bernstein kept a hold rating with a $24.00 target on May 13, 2026. The consensus among analysts is a strong buy, with an average target price of $38.25, based on 16 opinions.
About Dyne Therapeutics
Dyne Therapeutics, Inc. is a biotechnology company focused on developing treatments for neuromuscular diseases. Based in Waltham, Massachusetts, the company is working on a range of therapies for muscle diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and Pompe disease. Led by CEO Mr. John G. Cox, Dyne leverages its FORCE platform to deliver potential disease-modifying therapies. The company employs 263 people and was founded in 2017.
Bottom Line
Dirk Kersten's recent planned sales of Dyne Therapeutics shares highlight insider activity at the company. With a strong market position and a promising pipeline of treatments, Dyne remains a focus for investors. Analysts' strong buy consensus and high target prices reflect optimism about the company's potential, although these insights are based on past data and may not indicate current positions.
Get Dyne Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.